Present status of BCG immunotherapy of malignant melanoma
Morton, D. L. ; Eilber, F. R. ; Holmes, E. C. ; Sparks, F. C. ; Ramming, K. P.
Springer
Published 1976
Springer
Published 1976
| ISSN: |
1432-0851
|
|---|---|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Summary BCG systemic adjuvant immunotherapy may be effective for improving both the recurrence and survival rates in patients with regional metastases from malignant melanoma. Clinical trials show that many of the principles derived from the study of animal tumor systems are applicable to human cancer in that immunotherapy is most effective for a small residual number of tumor cells. BCG treatment fulfills many of the ideal criteria for adjuvant treatment following surgery when disease burden is lowest. It is relatively nontoxic; it is effective for disseminated melanoma; it has systemic activity in the adjuvant treatment of subclinical metastases. However, until clinical trials are complete, BCG adjuvant therapy must be considered investigational.
|
| Type of Medium: |
Electronic Resource
|
| URL: |